調節性T細胞(T regulator)：腫瘤免疫治療新標的

Regulatory T Cells: Potential Use in Anti-cancer Immunotherapy

莊其穆(Chi-Mou Juang) ； 葉濬毅(Jiun-Yih Yeh) ； 洪建夫(Chien-Fu Hung) ； 洪煥程(Huann-Cheng Horng) ； 屠乃方(Nae-Fong Twu) ； 鄭敏慧(Ming-Huei Cheng) ； 溫國璋(Kuo-Chang Wen) ； 袁九重(Chiou-Chung Yuan) ； 趙灌中(Kuan-Chong Chao) ； 吳子丑(T-C Wu) ； 顏明賢(Ming)

《中華民國婦癌醫學雜誌》 2007年1期 (2007/04) Pp. 1-10

https://doi.org/10.7010/JGO.200704.0001

摘要

有越來越多的證據顯示許多被自體毒殺性淋巴球所認識的腫瘤抗原其實是自體抗原。另外腫瘤免疫治療或者是輸入體外培養的毒殺性T淋巴細胞常會導致自體免疫疾病的產生，這種自體免疫疾病的產生多半是因爲腫瘤抗原與自體抗原交互作用而成。調節性T細胞目前被認爲與惡性腫瘤，自體免疫疾病，器官移植，以及懷孕有相關性。就對惡性腫瘤而言，由於耐受性T細胞會壓抑毒殺性T細胞的作用，因此如果能選用生物技術使調節性T細胞的數量或功能降低，將可以有效的增強抗腫瘤的免疫反應。由於目前研究顯示免疫調節性T細胞與腫瘤生成有很大相關性，由於抗腫瘤免疫反應同時也會導效免疫調節性T細胞的活化，因此設法將這些位淤腫瘤內的免疫調節性T細胞的功能或數量減弱將可以有效治療腫瘤。這種策略將可以使毒殺性T細胞的功能增加，也可以使目前的腫瘤免疫治療不管是DNA疫苗，樹狀細胞治療，或是勝肽疫苗治療都將使效果明顯增強。

關鍵字

調節性T細胞 ； 腫瘤免疫

並列摘要

There are accumulating demonstrations that many tumor antigens recognized by autologous cytotoxic lymphocytes are antigenically normal self-constitutents. Furthermore, immunotherapy of cancer by vaccination with tumor antigens or transfusion of ex vivo propagated cytotoxic lymphocytes often leads to the appearance of autoimmunity because of antigenic cross-reactions between tumor antigens and normal tissue antigens. It is now clear that CD4(superscript +) CD25(superscript +) T cells (T(subscript R) cells) actively hinder tumor immunity in cancer patients. Emerging data indicate that T(subscript R) cells might be generated to the same tumor-associated (self) antigens that comprise many candidate cancer vaccines. Removal of T(subscript R) cells lead to the activation of not only tumor-specific CD8(superscript +) CIL (and presumably tumor-specific CD4(superscript +) helper T cells). Using this strategy can devise a novel immunotherapy for cancer in humans or to make the current immunotherapies more effective, for example, by cytokine gene transduction in tumor cells, DNA vaccination, vaccination with tumor antigens! peptides or tumor antigen-pulsed dendritic cells.

並列關鍵字

Regulatory T cells ； Tumor immunology